当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.

The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.

Abstract：

BACKGROUND:Dexlansoprazole MR is a Dual Delayed Release formulation of dexlansoprazole, an enantiomer of lansoprazole, designed to extend the duration of acid suppression. AIM:To assess the 12-month safety of dexlansoprazole MR in patients with symptomatic gastro-oesophageal reflux disease (GERD). METHODS:In this randomised open-label study, patients received dexlansoprazole MR 60 or 90 mg once-daily for 12 months. Safety was evaluated at months 1, 3, 6, 9 and 12/final visit through physical examinations, laboratory evaluations, endoscopies, gastric biopsies, fasting serum gastrin values and adverse events (AEs). RESULTS:Of 591 patients receiving dexlansoprazole MR 60 and 90 mg, 71% and 65%, respectively, experienced ≥1 treatment-emergent AE; the most frequent AE was upper respiratory infection (14% and 13% in the 60- and 90-mg groups). Thirty patients experienced ≥1 serious AE; a majority of serious AEs were unrelated to study drug. No clinically meaningful change in any clinical laboratory parameters was noted. As expected, serum gastrin values rose with dexlansoprazole therapy; increases were not dose related. No clinically concerning trends were identified in gastric pathology results; no endocrine cell hyperplasia, adenocarcinoma, or lymphoma were observed. CONCLUSIONS:Twelve-month treatment with dexlansoprazole MR 60 and 90 mg was well tolerated by GERD patients in this study (Clinicaltrials.gov identifier NCT00255190).

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Dabholkar AH,Han C,Paris MM,Perez MC,Atkinson SN,Peura DA

doi

10.1111/j.1365-2036.2010.04519.x

subject

Has Abstract

pub_date

2011-02-01 00:00:00

pages

366-77

issue

3

eissn

0269-2813

issn

1365-2036

journal_volume

33

pub_type

杂志文章,多中心研究,随机对照试验

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial study.

    abstract：BACKGROUND:Bovine colostrum is a rich source of nutrients, antibodies and growth factors. AIM:To examine the efficacy of colostrum enemas in the treatment of distal colitis using a randomized, double-blind, controlled protocol. METHODS:Fourteen patients (eight female), with a mean age of 45 years (range, 16-75 years)...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2002.01354.x

    authors： Khan Z,Macdonald C,Wicks AC,Holt MP,Floyd D,Ghosh S,Wright NA,Playford RJ

    更新日期：2002-11-01 00:00:00

  • Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients.

    abstract：BACKGROUND:Chronic hepatitis C (HCV) treatment with pegylated-interferon (PEG-IFN)/ribavirin (RBV) is often limited by preexisting medical, psychiatric and psychosocial contraindications. However, limited data exist in general patient populations. AIM:To evaluate the percentage of HCV-infected patients in the general ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12200

    authors： Talal AH,LaFleur J,Hoop R,Pandya P,Martin P,Jacobson I,Han J,Korner EJ

    更新日期：2013-02-01 00:00:00

  • Allergy-related diseases and recurrent abdominal pain during childhood - a birth cohort study.

    abstract：BACKGROUND:Allergy and immune dysregulation may have a role in the pathophysiology of recurrent abdominal pain of functional origin, but previous studies of allergy-related diseases and abdominal pain have contradictory results. AIM:To examine the association between allergy-related diseases or sensitisation during ch...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12965

    authors： Olén O,Neuman Å,Koopmann B,Ludvigsson JF,Ballardini N,Westman M,Melén E,Kull I,Simrén M,Bergström A

    更新日期：2014-12-01 00:00:00

  • Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone.

    abstract：BACKGROUND:Grey Zone (GZ) is an ill-defined situation including patients falling between inactive carrier (IC) state and HBeAg-negative chronic hepatitis B (HBeAg-negative CHB). AIMS:To assess the long-term outcomes of GZ patients compared to IC in the absence of treatment. METHODS:Retrospective analysis of 287 IC an...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.14613

    authors： Bonacci M,Lens S,Mariño Z,Londoño MC,Rodríguez-Tajes S,Mas A,García-López M,Pérez-Del-Pulgar S,Sánchez-Tapias JM,Forns X

    更新日期：2018-05-01 00:00:00

  • Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance.

    abstract：BACKGROUND:Antibiotic resistance has increasingly been recognized as the major cause of treatment failure for Helicobacter pylori infection. New therapies for patients with metronidazole- or clarithromycin-resistant H. pylori are needed. AIM:To investigate the role of nitrofurantoin quadruple therapy for the treatment...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1046/j.1365-2036.2001.00945.x

    authors： Graham DY,Saeed MA,Hoffman J,El-Zimaity HM,Kwon DH,Osato MS

    更新日期：2001-04-01 00:00:00

  • Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies.

    abstract：BACKGROUND:The therapeutic efficacy of 5-aminosalicylic acid in inflammatory bowel disease may be related to its antioxidant properties. AIM:To compare in vitro the antioxidant effects of conventional drugs (5-aminosalicylic acid, corticosteroids, metronidazole), with new aminosalicylates (4-aminosalicylic acid, balsa...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.1999.00484.x

    authors： Simmonds NJ,Millar AD,Blake DR,Rampton DS

    更新日期：1999-03-01 00:00:00

  • Antigen stool test for assessment of Helicobacter pylori infection in patients with upper gastrointestinal bleeding.

    abstract：BACKGROUND:Re-bleeding of Helicobacter pylori-associated peptic ulcer disease is reduced by H. pylori eradication. AIM:To validate a non-invasive test, the Premium Platinum HpSA stool test, in patients with upper gastrointestinal bleeding. METHODS:Stool samples of consecutive patients with relevant bleeding from gast...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2003.01548.x

    authors： Peitz U,Leodolter A,Kahl S,Agha-Amiri K,Wex T,Wolle K,Günther T,Steinbrink B,Malfertheiner P

    更新日期：2003-04-01 00:00:00

  • Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors.

    abstract：BACKGROUND:The association between myocardial infarction (MI) and co-administration of proton pump inhibitors (PPIs) and clopidogrel remains controversial. AIM:To quantify the association between concomitant use of PPIs and clopidogrel and occurrence of recurrent MI. METHODS:We conducted a case-control study within a...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2010.04485.x

    authors： Valkhoff VE,'t Jong GW,Van Soest EM,Kuipers EJ,Sturkenboom MC

    更新日期：2011-01-01 00:00:00

  • Risk of colorectal adenomas in patients with coeliac disease.

    abstract：BACKGROUND:Coeliac disease is associated with an increased risk of lymphoma and small bowel malignancy, but most studies have found no increased risk of colorectal cancer. AIM:To compare the prevalence of colorectal adenomas in coeliac disease patients with that in non-coeliac disease controls. METHODS:We identified ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2010.04440.x

    authors： Lebwohl B,Stavsky E,Neugut AI,Green PH

    更新日期：2010-10-01 00:00:00

  • Pilot study: Gelafundin (polygeline) 4% plus antibiotics in the treatment of high-risk cirrhotic patients with spontaneous bacterial peritonitis.

    abstract：BACKGROUND:Cirrhotic patients with spontaneous bacterial peritonitis (SBP) have elevated rates of renal impairment and mortality. It has been shown that cefotaxime plus albumin infusion decrease renal impairment compared with antibiotic treatment alone, in patients with serum bilirubin >4 mg/dL or creatinine >1 mg/dL. ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2010.04309.x

    authors： Cartier M,Terg R,Lucero R,Muñoz A,Romero G,Levi D,Miguez C,Abecasis R

    更新日期：2010-07-01 00:00:00

  • Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease.

    abstract：BACKGROUND:Cross-sectional imaging techniques, including ultrasonography (US), computed tomography (CT) and magnetic resonance imaging (MRI), are increasingly used for evaluation of Crohn's disease (CD). Aim  To perform an assessment of the diagnostic accuracy of cross-sectional imaging techniques for diagnosis of CD, ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2011.04710.x

    authors： Panés J,Bouzas R,Chaparro M,García-Sánchez V,Gisbert JP,Martínez de Guereñu B,Mendoza JL,Paredes JM,Quiroga S,Ripollés T,Rimola J

    更新日期：2011-07-01 00:00:00

  • Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.

    abstract：BACKGROUND:Mesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis. AIM:To evaluate the efficacy of mesalazine suppositories in patients with ulcerative colitis (UC) and rectal inflammation; and in patient groups categorised by the extent...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/apt.12362

    authors： Watanabe M,Nishino H,Sameshima Y,Ota A,Nakamura S,Hibi T

    更新日期：2013-08-01 00:00:00

  • The risk of later surgery at the anastomotic site following right hemicolectomy for Crohn's disease in a national cohort of 12 230 patients.

    abstract：BACKGROUND:Crohn's disease (CD) has a high-risk of bowel resection and later surgery for recurrent disease. Recent guidelines recommend colonoscopy 6-12 months following surgery to reduce further surgical intervention through medical therapy intensification. AIMS:To investigate the risk of further surgery at the anast...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.16114

    authors： King D,Coupland B,Dosanjh A,Cole A,Adderley NJ,Reulen RC,Patel P,Trudgill NJ

    更新日期：2021-01-01 00:00:00

  • Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis.

    abstract：:Suppositories containing 300 mg 5-aminosalicylic acid (1.96 mmol) or 425 mg acetyl-5-aminosalicylic acid (1.96 mmol) were used in 40 patients with idiopathic proctitis to determine the efficacy of acetyl-5-aminosalicylic acid in treating this bowel inflammation. Each patient was treated with 5-aminosalicylic acid or a...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1988.tb00668.x

    authors： van Hogezand RA,van Hees PA,van Gorp JP,van Lier HJ,Bakker JH,Wesseling P,van Haelst UJ,van Tongeren JH

    更新日期：1988-02-01 00:00:00

  • The treatment of irritable bowel syndrome.

    abstract：:The efforts of clinical researchers, lay organizations and pharmaceutical companies have increased the public profile of irritable bowel syndrome and made it a respectable diagnosis. Diagnostic symptom criteria encourage a firm clinical diagnosis, which is the foundation of a logical management strategy. This begins w...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2002.01312.x

    authors： Thompson WG

    更新日期：2002-08-01 00:00:00

  • Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.

    abstract：AIM:To appraise the tolerance and efficacy of an induction of tolerance protocol to infliximab permitting the re-administration of the drug to patients with Crohn's disease having had infusion reactions requiring suspension of treatment. METHODS:Fourteen patients were included in the induction of tolerance protocol. E...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2006.03026.x

    authors： Duburque C,Lelong J,Iacob R,Seddik M,Desreumaux P,Fournier C,Wallaert B,Cortot A,Colombel JF

    更新日期：2006-09-01 00:00:00

  • Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy.

    abstract：BACKGROUND:There are patients with chronic hepatitis C who are not eligible for the current interferon-based therapies or refuse to be treated due to secondary effects. AIM:To provide information on alternative treatments for the management of these patients. METHODS:A PubMed search was performed to identify relevant...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.12562

    authors： Carreño V

    更新日期：2014-01-01 00:00:00

  • Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management.

    abstract：:A significant proportion of patients with gastro-oesophageal reflux disease (GERD) have Helicobacter pylori infection, but it is unclear whether or not H. pylori should be treated in this clinical setting. The aim of this review was to critically assess the relationship between H. pylori and GERD and its potential imp...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.1999.00460.x

    authors： O'Connor HJ

    更新日期：1999-02-01 00:00:00

  • Symptomatic improvement with one-year cisapride treatment in neuropathic chronic intestinal dysmotility.

    abstract：AIM:To assess the efficacy of a prokinetic agent in the long-term treatment of chronic intestinal dysmotility and the influence of extrinsic denervation. METHODS:We assessed symptoms, compliance and untoward effects in an open, 1-year trial of cisapride, 20 mg t.d.s., in 37 patients with neuropathic forms of chronic i...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.0953-0673.1996.00403.x

    authors： Camilleri M,Balm RK,Zinsmeister AR

    更新日期：1996-06-01 00:00:00

  • Review article: COVID-19 and liver disease-what we know on 1st May 2020.

    abstract：BACKGROUND:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19), became a global threat to human health. Liver impairment has been frequently reported as a common manifestation, although its clinical significance is still unclear, particularly in pa...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.15813

    authors： Garrido I,Liberal R,Macedo G

    更新日期：2020-07-01 00:00:00

  • Selective COX-2 inhibitors and human inflammatory bowel disease.

    abstract：BACKGROUND:Much recent effort has been made to produce selective inhibitors of cyclo-oxygenase-2 (COX-2) in the belief that these will lack the gastrointestinal damaging effects of traditional non-steroidal anti-inflammatory drugs (NSAIDs). Inflammatory bowel disease is associated with increased local production of pro...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.1999.00585.x

    authors： McCartney SA,Mitchell JA,Fairclough PD,Farthing MJ,Warner TD

    更新日期：1999-08-01 00:00:00

  • Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease.

    abstract：BACKGROUND:Infliximab reduces mucosal inflammation in some, but not all, patients with Crohn's disease. AIM:To monitor clinical data and changes in mucosal cytokine levels after infliximab treatment to identify differences between responders and non-responders. METHODS:Twenty-six patients with fistulating Crohn's dis...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2003.01487.x

    authors： Agnholt J,Dahlerup JF,Buntzen S,Tøttrup A,Nielsen SL,Lundorf E

    更新日期：2003-03-01 00:00:00

  • Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice.

    abstract：BACKGROUND:Peginterferon-alpha-based therapy frequently leads to neutropenia. It remains unclear whether neutropenia is associated with bacterial infection in chronic hepatitis C (CHC). AIM:To evaluate the risk of bacterial infection and neutropenia in patients with CHC treated with peginterferon-alpha/ribavirin. MET...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2009.03957.x

    authors： Yang JF,Hsieh MY,Hou NJ,Dai CY,Huang JF,Lin ZY,Chen SC,Hsieh MY,Wang LY,Chuang WL,Yu ML

    更新日期：2009-05-01 00:00:00

  • Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.

    abstract：BACKGROUND:The guaiac faecal occult blood test (G-FOBT), HemoccultSENSA, is sensitive for significant neoplasms [colorectal cancer (CRC), advanced adenomatous polyps (AAP)], but faulted by non-specificity for human haemoglobin (Hb). Quantified, Hb- specific, immunochemical faecal occult blood tests (I-FOBT) are now use...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03898.x

    authors： Rozen P,Levi Z,Hazazi R,Waked A,Vilkin A,Maoz E,Birkenfeld S,Niv Y

    更新日期：2009-02-15 00:00:00

  • Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.

    abstract：BACKGROUND:Studies to date have not directly compared the pharmacodynamic efficacies of different proton pump inhibitors in controlling intragastric acidity in patients treated with non-steroidal anti-inflammatory drugs. AIM:To compare acid suppression with once-daily esomeprazole 40 mg, lansoprazole 30 mg and pantopr...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2006.02867.x

    authors： Goldstein JL,Miner PB Jr,Schlesinger PK,Liu S,Silberg DG

    更新日期：2006-04-15 00:00:00

  • Do mucosal defensive agents improve the cure rate when used with dual or triple therapy regimens for eradicating Helicobacter pylori infection?

    abstract：BACKGROUND:Some of mucosal defensive agents have anti-Helicobacter pylori activities. However, their effectiveness in eradicating H. pylori infection has not been evaluated. AIM:To assess the additive effect of mucosal defensive agents in eradication regimens using statistical analysis. METHODS:Pertinent studies were...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1046/j.1365-2036.2000.00692.x

    authors： Hojo M,Miwa H,Kikuchi S,Sato N

    更新日期：2000-02-01 00:00:00

  • Higher plasma vitamin D is associated with reduced risk of Clostridium difficile infection in patients with inflammatory bowel diseases.

    abstract：BACKGROUND:Patients with inflammatory bowel diseases (IBD) have an increased risk of clostridium difficile infection (CDI). Cathelicidins are anti-microbial peptides that attenuate colitis and inhibit the effect of clostridial toxins. Plasma calcifediol [25(OH)D] stimulates production of cathelicidins. AIM:To examine ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/apt.12706

    authors： Ananthakrishnan AN,Cagan A,Gainer VS,Cheng SC,Cai T,Szolovits P,Shaw SY,Churchill S,Karlson EW,Murphy SN,Kohane I,Liao KP

    更新日期：2014-05-01 00:00:00

  • Histomorphological differentiation of non-erosive reflux disease and functional heartburn in patients with PPI-refractory heartburn.

    abstract：BACKGROUND:Proton pump inhibitor (PPI)-refractory heartburn may be due to persistent gastro-oesophageal reflux, oesophageal hypersensitivity or functional heartburn (FH). The differentiation between non-erosive reflux disease (NERD) and FH may be very difficult. However, this differentiation is important for appropriat...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12428

    authors： Kandulski A,Jechorek D,Caro C,Weigt J,Wex T,Mönkemüller K,Malfertheiner P

    更新日期：2013-09-01 00:00:00

  • Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.

    abstract：BACKGROUND:The epidemiology and pathophysiology of non-erosive gastro-oesophageal reflux disease differs from erosive gastro-oesophageal reflux disease. There is a possibility that non-erosive gastro-oesophageal reflux disease treatment requires a different regimen/approach but it is not yet acknowledged. AIM:To inves...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.2005.02467.x

    authors： Wada T,Sasaki M,Kataoka H,Tanida S,Itoh K,Ogasawara N,Oshima T,Togawa S,Kubota E,Yamada T,Mori Y,Fujita F,Ohara H,Nakao H,Sobue S,Joh T,Itoh M

    更新日期：2005-06-01 00:00:00

  • Differential effects of baclofen on lower oesophageal sphincter pressure and proximal gastric motility in humans.

    abstract：BACKGROUND:The gamma-aminobutyric acid receptor type B agonist, baclofen, inhibits transient lower oesophageal sphincter relaxations by influencing a vagal pathway. Although post-prandial proximal gastric function, which is vagally mediated, is important in the occurrence of transient lower oesophageal sphincter relaxa...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2003.01605.x

    authors： Lee KJ,Vos R,Janssens J,Tack J

    更新日期：2003-07-15 00:00:00